Roche pushes Tecentriq combos into PhIII melanoma trials

Roche is planning to initiate late-stage studies investigating potential combinations for patients with advanced skin cancer based on its immunotherapy Tecentriq, which is already on the market for lu…
Read the full story: PharmaTimes: News RSS